5-Hydroxyeicosatetraenoic acid

5-Hydroxyeicosatetraenoic acid
Names
IUPAC name
(5S,6E,8Z,11Z,14Z)-5-Hydroxyicosa-6,8,11,14-tetraenoic acid
Other names
5-HETE, 5(S)-HETE
Identifiers
70608-72-9 N
3D model (Jmol) Interactive image
Interactive image
ChEBI CHEBI:28209 YesY
ChEMBL ChEMBL164813 YesY
ChemSpider 4444314 YesY
ECHA InfoCard 100.161.309
3390
PubChem 5280733
Properties
C20H32O3
Molar mass 320.47 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

5-Hydroxyicosatetraenoic acid (5-HETE, 5(S)-HETE, or 5S-HETE) is an eicosanoid, i.e. a metabolite of arachidonic acid, made by a wide variety of cell types of mammals and other animal species. It along with several closely related metabolites are hormone-like autocrine and paracrine signalling agents. In these roles, the 5-HETE family metabolites can amplify or dampen inflammation and allergy responses to disturbances in various animal species. Similar functions in humans, while strongly suggested by animal and tissue studies, requires further Translational research.

Nomenclature

5-Hydroxyicosatetraenoic acid is more properly termed 5(S)-hydroxyicosatetraenoic acid or 5(S)-HETE) to signify the (S) stereochemical configuration of its 5-hydroxy residue as opposed to its 5(R)-hydroxyicosatetraenoic acid (i.e., 5(R)-HETE) stereoisomer. Since 5(R)-HETE was rarely detected in studies of animals including humans, much of the older and some of the newer literature refers to 5(S)-HETE as 5-HETE. Its IUPAC name, (5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoic acid, defines 5(S)-HETE's structure unambiguously by notating not only its S-hydroxyl chirality but also the cis–trans isomerism geometry for each of its 4 double bonds; E signifies trans and Z signifies cis double bond geometry. The literature commonly uses an alternate but still unambiguous name for 5(S)-HETE viz., 5(S)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid.

History of discovery

The Nobel laureate, Bengt I. Samuelsson, and colleagues first described 5(S)-HETE in 1976 as a metabolite of arachidonic acid made by rabbit neutrophils.[1] Biological activity was linked to it several years later when it was found to stimulate human neutrophil rises in cytosolic calcium, chemotaxis, and increases in their cell surface adhesiveness as indicated by their aggregation to each other.[2] Since a previously discovered arachidonic acid metabolite made by neutrophils, leukotriene B4 (LTB4), also stimulates human neutrophil calcium rises, chemotaxis, and auto-aggregation and is structurally similar to 5(S)-HETE in being a 5-(S)-hydroxy-eicosateraenoate, it was assumed that 5-(S)-HETE stimulated cells through the same Cell surface receptors as those used by (LTB4) viz., the Leukotriene B4 receptors. However, further studies in neutrophils indicated that 5-(S)-HETE acted through a receptor distinct from that used by LTB4 as well as various other neutrophil stimuli, the Oxoeicosanoid receptor 1 (OXER1).[3][4]

5-(S)-HETE synthesis

5(S)-HETE is a product of the cellular metabolism of the n-6 Polyunsaturated fatty acid, arachidonic acid (i.e. 5Z,8Z,11Z,14Z-eicosatetraenoic acid), by ALOX5 (also termed arachidonate-5-lipoxygenase, 5-lipoxygenase, 5-LO, and 5-LOX). ALOX5 metabolizes arachidonic acid to its hydroperoxide derivative, Arachidonic acid 5-hydroperoxide i.e. 5S-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid (5(S)-HpETE). 5-(S)-HpETE may then be release and rapidly converted to 5(S)-HETE by ubiquitous cellular peroxidases:

5Z,8Z,11Z,14Z-eicosatetraenoic acid + O2 → 5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid → 5(S)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid

Alternatively, 5(S)-HpETE may be further metabolized to its epoxide, 5(6)-oxido-eicosatetraenoic acid (i.e. leukotriene A4 (LXA4) or S,6S-oxido-7E,9E,11Z,14Z-eicosatetraenoic acid) which may then be further metabolized to leukotriene B4 by Leukotriene A4 hydrolase or to leukotriene C4 by Leukotriene C4 synthase; leukotriene C4 may then be further metabolized to Leukotriene D4 and Leukotriene E4.[5] The relative amounts of these metabolites made by specific cells and tissues depends in large part on the relative content of the appropriate enzymes.

Distribution of 5-(S)-HETE-synthesizing cells

Human ALOX5 and its 5(S)-HETE synthesizing capacity are highly expressed primarily in cells that regulate innate immunity host defense inflammation responses and allergy responses such as neutrophils, eosinophils, B lymphocytes, and monocytes, monocyte-derived tissue macrophages, dendritic cells, foam cells in atherosclerosis tissues, and tissue mast cells.[5] ALOX5 may also be expressed at relatively low levels in a variety of other cell types but is seems more likely that 5(S)-production in most tissues, such as those of the vasculature, is mediated by the blood and tissue cells just sited.[6] However, human prostate, lung, colon, colorectal and pancreatic cancer cells may express or overexpress ALOX5 as a consequence of their malignant transformation.[7]

Further metabolism of 5-(S)-HETE

In addition to its intrinsic activity, 5(S)-ETE can serve as an intermediate in that it may be converted to other bioactive products. Importantly, the NADP+-dependent enzyme, 5-Hydroxyeicosanoid dehydrogenase (5-HEDH) metabolizes it form 5-oxo-eicosatetraenoic acid (i.e. 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoate or 5-oxo-ETE):

5(S)-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid +NADP+ 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoate + NADPH

5-Oxo-ETE is some 30- to 100-fold more potent than 5(S)-HETE and therefore may be a critical product among the products formed from 5(S)-HETE. Note that this conversion reaction is bidirectional: 5-oxo-ETE is rapidly converted back to 5(S)-HETE by 5-NEDH + NADPH. Indeed, the 5(S)-HETE-to-5-oxo-ETE transformation is regulated, making 5-oxo-ETE only in neutrophils undergoing severe oxidative stress or when near to 5-NEDH-containing cell types in tissues undergoing inflammatory, allergic, cancerous transformation, or other stress reactions. Thus, a) neutrophils make 5-(S)-HETE but little or no 5-oxo-ETE unless undergoing severe oxidative stresses that causes them to greatly increase their levels of NADP+ and b) neutrophils can release 5(S)-HETE to, e.g. epithelial, endothelial, dendritic, and certain (e.g. prostate, breast, and lung) cancer cells which display little or no 5-LO activity but have high levels of 5-NEDH activity and thereby metabolize the released 5(S)-HETE to 5-oxo-ETE.[8]

Certain cells such as the human neutrophil may further metabolize 5-(S)-HETE. First, cells use a acyltransferase-dependent acylation reaction to esterify 5(S)-HETE into the phospholipids of cell membranes; this reaction could serve as means for storing 5(S)-HETE for release during subsequent cell stimulation or, alternatively, alter the properties of cell membranes in functionally important ways. Second, cells use a C-20 hydroxylase, cytochrome P450 (probably CYP4F3), to metabolize 5(S)-HETE to 5-(S),20-dihydroxy-eicosatetraenoate (5,20-diHETE); since 5,20-diHETE is ~50- to 100-fold weaker than 5(S)-HETE in stimulating cells, this metabolism is proposed to represent a pathway for 5(S)-HETE inactivation. Third, cells, particularly human eosinophils, use ALOX15 to metabolize 5(S)-HETE to 5-(S),15-(S)-dihydroxy-eicosatetraenoate (5,15-diHETE); 5,15-diHETE is ~3- to 10-fold weaker than 5(S)-HETE in stimulating cells. And, forth, cells use 12-lipoxygenase (i.e. ALOX12 to metabolize 5(S)-HETE to 5(S),12(S)-diHETE, cyclooxygenase-2 to metabolize 5(S)-HETE to 5-(S),15(R)-diHETE and 5-(S),11(R)-diHETE, and aspirin-treated cyclooxygenase-2 to metabolize 5(S)-HETE to 5-(S),15(R)-diHETE; these metabolites have yet to be evaluated for activity.[2][8][9][10][11]

Alternate pathways that make some of the above products include the: a) metabolism of 5(S)-HpETE to 5-oxo-ETE by cytochrome P450 (CYP) enzymes such as CYP1A1, CYP1A2, CYP1B1, and CYP2S1; b) conversion of 5-HETE to 5-oxo-ETE non-enzymatically by heme or other dehydrating agents; c) the formation of 5-oxo-15-(S)-hydroxy-ETE through 5-HEDH-based oxidation of 5-(S),15-(S)-dihydroxyicosatetraenoate; d) formation of 5-(S),15(R)-dihydroxy-eicosatetraenoate by the attack of ALOX5 on 15-hydroxyicosatetraenoic acid (15-(S)-HETE); e) formation of 5-oxo-15-(S)-hydroxy-eicosatetreaenoate (5-oxo-15-(S)-hydroxy-ETE) by the arachidonate 15-Lipoxygenase-1-based or arachidonate 15-lipoxygenased-2-based metabolism of 5-oxo-ETE; and f) the conversion of 5-(S)-HpETE and 5(R)-HpETE to 5-oxo-ETE by the action of a mouse macrophage 50-60 kilodalton cytosolic protein.[8]

Mechanism of action

The OXER1 receptor

5-(S)-HETE family members share a common receptor target for stimulating cells that differs from and receptors targeted by the other major products of ALOX5, i.e., leukotriene B4, leukotriene C4, leukotriene D4, leukotriene E4, lipoxin A4, and lipoxin B4; members of the 5-(S)-HETE family stimulate cells primarily by binding and thereby activating a dedicated G protein-coupled receptor, the oxoeicosanoid receptor 1 or OXER1 (also termed OXE, OXE-R, hGPCR48, HGPCR48, or R527 receptor); OXER1's gene is sometimes termed OXE1.[8][12] OXER1 couples to the G protein complex composed of the Gi alpha subunit (Gαi) and G beta-gamma complex (Gβγ); when bound to a 5-(S)-HETE family member, OXER1 triggers this G protein complex to dissociate into its Gαi and Gβγ components with Gβγ appearing to be the component responsible for activating the signal pathways which lead to cellular functional responses.[8] The cell-activation pathways stimulated by OXER1 include those mobilizing ionic calcium and activating MAPK/ERK, p38 mitogen-activated protein kinases, cytosolic Phospholipase A2, PI3K/Akt, and protein kinase C beta and epsilon.[8][13]

Other GPCR receptors

Mouse MA-10 cells respond to 5-oxo-ETE but lack OXER1. It has been suggested that these cells' responses to 5-oxo-ETE are mediated by an ortholog to OXER1, mouse niacin receptor 1, Niacr1, which is a G protein-coupled receptor for niacin, or, alternatively, by one or more of the mouse hydroxycarboxylic acid (HCA) family of the G protein-coupled receptors, HCA1 (GPR81), HCA2 (GPR109A), and HCA3 (GPR109B), which are G protein-coupled receptors for fatty acids.[14]

The PPARγ receptor

5-Oxo-15(S)-hydroxy-ETE and to a lesser extent 5-oxo-ETE but not 5-(S)-HETE also bind to and activate peroxisome proliferator-activated receptor gamma (PPARγ). This activation does not proceed through OXER1; rather, it involves the direct binding of the oxo analogs to PPARγ with 5-oxo-15-(S)-HETE being more potent in binding and activating PPARγ.[15] Activation of OXER1 receptor and PPARγ by the oxo analogs can have opposing effects on cell function. For example, 5-oxo-ETE-bound OXER1 stimulates whereas 5-oxo-ETE-bound PPARγ inhibits the proliferation of various types of human cancer cell lines; this results in 5-oxo-ETE and 5-oxo-15-(S)-HETE having considerably less potency than anticipated in stimulating these cancer cells to proliferate relative to the potency of 5-(S)-HETE, a relationship not closely following the potencies of these three compounds in activating OXER1.[15]

Other mechanisms

5-(S)-HETE acylated into the phosphatidylethanolamines fraction of human neutrophil membranes is associated with the inhibition of these cells from forming neutrophil extracellular traps, i.e. extracellar DNA scaffolds which contain neutophil-derived antimicrobial proteins that circulate in blood and have the ability to trap bacteria.[16] It seems unlikely that this inhibition reflects involvement of OXER1.

5-Oxo-ETE relaxes pre-contracted human bronchi by a mechanism that does not appear to involve OXER1 but is otherwise undefined.[13][17]

Potencies of 5-HETE family members and metabolites

5(S)-HETE is commonly converted to other members of the 5-(S)-HETE family members which may contribute to 5(S)-HETEs bioactivities by mimicking 5(S)-HETE in binding to the OXER1 receptor. The relative potencies of these family members in binding to the neutrophil OXER1 receptor and stimulating this cells are about 100, 30, 5-10, 1-3, 1-3, 1, <1 for 5-oxo-ETE, 5-oxo-15(S)-HETE, 5-(S)-HETE, 5-(S),15-(S)-dihete, 5-oxo-20-hydroxy-ETE, 5-(S),20-diHETE, and 5,15-dioxo-ETE, respectively; it is anticipated that they will show similar relative potencies in stimulating other OXER1-bearing ells.[3][13][18]

Clinical significance

Inflammation

5(S)-HETE and other family members were first detected as products of arachidonic acid made by stimulated human polymorphonuclear neutrophils (PMN), a leukocyte blood cell type involved in host immune defense against infection but also implicated in aberrant pro-inflammatory immune responses such as arthritis; soon thereafter they found to be active also in stimulating these cells to migrate (i.e. chemotaxis), degranulate (i.e. release the anti-bacterial and tissue-injuring contents of their granules), produce bacteriocidal and tissue-injuring reactive oxygen species, and mount other pro-defensive as well as pro-inflammatory responses of the Innate immune system. For example, the gram-negative bacterium, Salmonella tryphimurium, and the outer surface of gram negative bacteria, Lipopolysaccharide, promote the production of 5-(S)-HETE and 5-oxo-ETE by human neutrophils. The family members stimulate another blood cell of the innate immunity system, the human monocyte, acting synergistically with the pro-inflammatory CC chemokines, monocyte chemotactic protein-1 and monocyte chemotactic protein-3, to stimulate monocyte function. 5-Oxo-ETE also stimulates two other cell types that share responsibility with the PMN for regulating inflammation, the human lymphocyte and dendritic cell. And, in vivo studies, the injection of 5-oxo-ETE into the skin of human volunteers causes the local accumulation of PMN and monocyte-derived macrophages.[13] Furthermore, the production of one or more 5(S)-HETE family members as well as the expression of orthologs of the human OXER1 receptor occur in various mammalian species including dogs, cats, cows, sheep, elephants, pandas, opossums, and ferrets and in several species of fish; for example, cats undergoing experimentally induced asthma accumulate 5-oxo-ETE in their lung lavage fluid, feline leucocytes make as well as respond to 5-oxo-ETE by an oxer1-dependent mechanism; and an OXER1 ortholog and, apparently, 5-oxo-ETE are necessary for the inflammatory response to tissue damage caused by osmolarity insult in zebrafish.[8][19][20]

These results given above suggest that members of the 5-oxo-ETE family and the OXER1 receptor or its orthologs may contribute to protection against microbes, the repair of damaged tissues, and pathological inflammatory responses in humans and other animal species.[8] However, an OXER1 ortholog is absent in mice and other rodents; while rodent tissues do exhibit responsiveness to 5-oxo-ETE, the lack of an oxer1 or other clear 5-oxoETE receptor in such valued animal models of diseases as rodents has impeded progress in our understanding of the physiological and pathological roles of 5-oxo-ETE.[20]

Allergy

The following human cell types or tissues that are implicated in allergic reactivity produce 5-HETE (stereoisomer typically not defined): alveolar macrophages isolated from asthmatic and non-asthmatic patients, basophils isolated from blood and challenged with anti-IgE antibody, mast cells isolated from lung, cultured pulmonary artery endothelial cells, isolated human pulmanary vasculature, and allergen-sensitized human lung specimens challenged with specific allergen.[13][21] Additionally, cultured human airway epithelial cell lines, normal bronchial epithelium, and bronchial smooth muscle cells convert 5-(S)-HETE to 5-oxo-ETE in a reaction that is greatly increase by oxidative stress, which is a common component in allergic inflammatory reactions.[13] Finally, 5-HETE is found in the bronchoalveolar lavage fluid of asthmatic humans and 5-oxo-ETE is found in the bronchoalveolar lavage fluid of cats undergoing allergen-induced bronchospasm.[13][20][22]

Among the 5-HETE family of metabolites, 5-oxo-ETE is implicated as the most likely member to contribute to allergic reactions. It has exceptionally high potency in stimulating the chemotaxis, release of granule-bound tissue-injuring enzymes, and production of tissue-injuring reactive oxygen species of a cell type involved in allergic reactions, the human eosinophil granulocyte.[13] It is also exceptionally potent in stimulating eosinophils to activate cytosolic phospholipase A2 (PLA2G4A) and possibly thereby to form platelet-activating factor (PAF) as well as metabolites of the 5-HETE family.[13][23] PAF is itself a proposed mediator of human allergic reactions which commonly forms concurrently with 5-HETE family metabolites in human leukocytes and acts synergistically with these metabolites, particularly 5-oxo-ETE, to stimulate eosinophils.[13][24][25][26] 5-Oxo-ETE also cooperates positively with at least four other potential contributors to allergic reactions, RANTES, Eotaxin, Granulocyte macrophage colony-stimulating factor, and granulocyte colony-stimulating factor in stimulating human eoxinophils and is a powerful stimulator of chemotaxis in another cell type contributing to alleric reactions, the human basophil granulocyte.[13] Finally, 5-oxo-ETE stimulates the infiltration of eosinophils into the skin of humans following its intradermal injection (its actions are more pronounced in asthmatic compared to healthy subjects) and when instilledd into the trachea of Brown Norway rats causes eosinophils to infiltrate lung.[13] These results suggest that the 5-oxo-ETE made at the initial tissue site of allergen insult acting through the OXER1 on target cells attracts circulating eosinophils and basophils to lung, nasal passages, skin, and possibly other sites of allergen deposition to contribute to asthma, rhinitis, and dermatitis, and other sites of allergic reactivity.[13][27]

The role of 5-HETE family agonists in the bronchoconstriction of airways (a hallmark of allergen-induced asthma) in humans is currently unclear. 5-HETE stimulates the contraction of isolated human bronchial muscle, enhances the ability of histamine to contract this muscle, and contracts guinea pig lung strips.[28] 5-Oxo-ETE also stimulates contactile responses in fresh bronchi, cultured bronchi, and cultured lung smooth muscle taken from guinea pigs but in direct contrast to these studies is reported to relax bronchi isolated from humans.[17][29][30] The latter bronchi contractile responses were blocked by cyclooxygenase-2 inhibition or a thromboxine A2 receptor antagonist and therefore appear mediated by 5-oxo-ETE-induced production of this thromboxane. In all events, the relaxing action of 5-oxo-ETE on human bronchi does not appear to involve OXER1.[13]

Cancer

The 5-oxo-ETE family of agonists have also been proposed to contribute to the growth of several types of human cancers. This is based on their ability to stimulate certain cultured human cancer cell lines to proliferate, the presence of OXER1 mRNA and/or protein in these cell lines, the production of 5-oxo-ETE family members by these cell lines, the induction of cell death (i.e. apoptosis) by inhibiting 5-lipoxygenase in these cells, and/or the overexpression of 5-lipoxygenase in tissue taken form the human tumors. Human cancers whose growth has been implicated by these studies as being mediated at least in part by a member(s) of the 5-oxo-ETE family include those of the prostate, breast, lung, ovary, and pancreas.[13][15][31][32]

Steroid production

5-(S)-HETE and 5-(S)-HpETE stimulate the production of progesterone by cultured rat ovarian glomerulosa cells[33] and enhance the secretion of progesterone and testosterone by cultured rat testicular Leydig cells.[34] Both metabolites are made by Cyclic adenosine monophosphate-stimulated MA-10 mouse leydig cells; stimulate these cells to transcribe Steroidogenic acute regulatory protein, and in consequence produce the steroids.[35][36] The results suggest that trophic hormones (e.g., leutenizing hormone, adrenocorticotropic hormone) stimulate these steroid producing cells to make 5-(S)-HETE and 5-(S)HpEPE which in turn increase the synthesis of steroidogenic acute regulatory protein; the latter protein promotes the rate-limiting step in steroidogenesis, transfer of cholesterol from the outer to the inner membrane of mitochondria and thereby acts in conjunction with trophic hormone-induce activation of protein kinase A to make progesterone and testosterone.[37] This pathway may also operate in humans: Human H295R adrenocortical cells do express OXER1 and respond to 5-oxo-ETE by an increasing the transcription of steroidogenic acute regulatory protein messenger RNA as well as the production of aldosterone and progesterone by an apparent OXER1-dependent pathway.[14]

Rat and mouse cells lack OXER1. It has been suggested that the cited mouse MA-10 cell responses to 5-oxo-ETE are mediated by an ortholog to OXER1, mouse niacin receptor 1, Niacr1, which is a G protein-coupled receptor mediating the activity of niacin, or by one or more of the mouse hydroxycarboxylic acid (HCA) family of the G protein-coupled receptors, HCA1 (GPR81), HCA2 (GPR109A), and HCA3 (GPR109B), which are G protein-coupled receptors for fatty acids.[14] In any event, Human H295R adrenocortical cells do express OXER1 and respond to 5-oxo-ETE by an increasing the transcription of steroidogenic acute regulatory protein messenger RNA as well as the production of aldosterone and progesterone by an apparent OXER1-dependent pathway.[14]

Bone remodeling

In an in vitro mixed culture system, 5-(S)-HETE is released by monocytes to stimulate, at sub-nanamolar concentrations, osteoclast-dependent bone reabsorption.[38] It also inhibits morphogenetic protein-2 (BMP-2)-induced bone-like nodule formation in mouse calvarial organ cultures.[39] These results allow that 5-(S)-HETE and perhaps more potently, 5-oxo-ETE contribute to the regulation of bone remodeling.

Parturition

5(S)-HETE) is: elevated in the human uterus during labor;[40] at 3-150 nM, increases both the rates of spontaneous contractions and overall contractility of myometrial strips obtained at term but prior to labor from human lower uterine segments;[41] and in an in vitro system crosses either amnion or intact amnion-chorion-decidua and thereby maym along with prostaglandin E2 move from the amnion to uterus during labor in humans.[42] These studies allow that 5(S)-HETE, perhaps in cooperation with established role of prostaglandin E2, may play a role in the onset of human labor.

Other actions

5(S)-HETE is reported to modulate tubuloglomerular feedback.[43] 5(S)-HpETE is also reported to inhibit the Na+/K+-ATPase activity of Synaptosome membrane preparations prepared from ratcerebral cortex and may thereby inhibit synapse-dependent communications between neurons.[44]

5(S)-HETE acylated into phosphatidylethanolamine is reported to increase the stimulated production of superoxide anion and interlukin-8 release by isolated human neutrophils and to inhibit the formation of Neutrophil extracellular traps (i.e. NETS); NETS trap blood-circulating bacteria to assist in their neutralization).[16] 5(S)-HETE esterified to phosphatidylcholine and glycerol esters by human endothelial cells is reported to be associated with the inhibition of prostaglandin production.[45]

Possible alternative receptor

Progress in proving the role of the 5-HETE family of agonists and their OXER1 receptor in human physiology and disease has been made difficult because mice and rats, which are the most common in vivo models for investigating these issues, lack OXER1; this receptor is expressed in non-human primates and a wide range of other mammals as well as various species of fish but not in the rodents so far tested.[13] A model of allergic airways disease in cats, which express OXER1 and make 5-oxo-ETE has recently been developed for such studies.[20]

The mouse ortholog of the human Niacin receptor 1 (NIACR1), Niacr1, has been proposed to mediate the action of 5-oxo-ETE on mouse Leydig cells.[14] The roles, if any, of Niacr1 in the response of these leydig cells to other 5-HETE family members as well as in the response of other mouse cells and tissues to 5-HETE family members and the role of Niacr1 orthologs in the response of human and other species tissues to 5-HETE family members has not been determined.

See also

References

  1. ↑ Borgeat P, Hamberg M, Samuelsson B (December 1976). "Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases". The Journal of Biological Chemistry. 251 (24): 7816–20. PMID 826538.
  2. 1 2 Rossi AG, O'Flaherty JT (December 1991). "Bioactions of 5-hydroxyicosatetraenoate and its interaction with platelet-activating factor". Lipids. 26 (12): 1184–8. doi:10.1007/bf02536528. PMID 1668115.
  3. 1 2 O'Flaherty JT, Taylor JS, Thomas MJ (December 1998). "Receptors for the 5-oxo class of eicosanoids in neutrophils". The Journal of Biological Chemistry. 273 (49): 32535–41. doi:10.1074/jbc.273.49.32535. PMID 9829988.
  4. ↑ Powell WS, Rokach J (Mar 2005). "Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE". Progress in Lipid Research. 44 (2–3): 154–83. doi:10.1016/j.plipres.2005.04.002. PMID 15893379.
  5. 1 2 Rådmark O, Werz O, Steinhilber D, Samuelsson B (April 2015). "5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease". Biochimica et Biophysica Acta. 1851 (4): 331–9. doi:10.1016/j.bbalip.2014.08.012. PMID 25152163.
  6. ↑ Osher E, Weisinger G, Limor R, Tordjman K, Stern N (June 2006). "The 5 lipoxygenase system in the vasculature: emerging role in health and disease". Molecular and Cellular Endocrinology. 252 (1–2): 201–6. doi:10.1016/j.mce.2006.03.038. PMID 16647809.
  7. ↑ Bishayee K, Khuda-Bukhsh AR (September 2013). "5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy". Acta Biochimica et Biophysica Sinica. 45 (9): 709–19. doi:10.1093/abbs/gmt064. PMID 23752617.
  8. 1 2 3 4 5 6 7 8 Powell WS, Rokach J (April 2015). "Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid". Biochimica et Biophysica Acta. 1851 (4): 340–55. doi:10.1016/j.bbalip.2014.10.008. PMID 25449650.
  9. ↑ Serhan CN (2005). "Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution". Prostaglandins, Leukotrienes, and Essential Fatty Acids. 73 (3–4): 141–62. doi:10.1016/j.plefa.2005.05.002. PMID 16005201.
  10. ↑ Tejera N, Boeglin WE, Suzuki T, Schneider C (January 2012). "COX-2-dependent and -independent biosynthesis of dihydroxy-arachidonic acids in activated human leukocytes". Journal of Lipid Research. 53 (1): 87–94. doi:10.1194/jlr.M017822. PMC 3243484Freely accessible. PMID 22068350.
  11. ↑ Romano, M; Cianci, E; Simiele, F; Recchiuti, A (2015). "Lipoxins and aspirin-triggered lipoxins in resolution of inflammation". European Journal of Pharmacology. 760: 49–63. doi:10.1016/j.ejphar.2015.03.083. PMID 25895638.
  12. ↑ O'Flaherty JT, Rossi AG (July 1993). "5-hydroxyicosatetraenoate stimulates neutrophils by a stereospecific, G protein-linked mechanism". The Journal of Biological Chemistry. 268 (20): 14708–14. PMID 8392058.
  13. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Powell WS, Rokach J (October 2013). "The eosinophil chemoattractant 5-oxo-ETE and the OXE receptor". Progress in Lipid Research. 52 (4): 651–65. doi:10.1016/j.plipres.2013.09.001. PMID 24056189.
  14. 1 2 3 4 5 Cooke M, Di Cónsoli H, Maloberti P, Cornejo Maciel F (May 2013). "Expression and function of OXE receptor, an eicosanoid receptor, in steroidogenic cells". Molecular and Cellular Endocrinology. 371 (1–2): 71–8. doi:10.1016/j.mce.2012.11.003. PMID 23159987.
  15. 1 2 3 O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, Clay CE, High K, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, Cramer SD, Morrow CS (October 2005). "5-Oxo-ETE analogs and the proliferation of cancer cells". Biochimica et Biophysica Acta. 1736 (3): 228–36. doi:10.1016/j.bbalip.2005.08.009. PMID 16154383.
  16. 1 2 Clark SR, Guy CJ, Scurr MJ, Taylor PR, Kift-Morgan AP, Hammond VJ, Thomas CP, Coles B, Roberts GW, Eberl M, Jones SA, Topley N, Kotecha S, O'Donnell VB (February 2011). "Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection". Blood. 117 (6): 2033–43. doi:10.1182/blood-2010-04-278887. PMC 3374621Freely accessible. PMID 21177434.
  17. 1 2 Morin C, Sirois M, Echave V, Gomes MM, Rousseau E (June 2007). "Relaxing effects of 5-oxo-ETE on human bronchi involve BK Ca channel activation". Prostaglandins & Other Lipid Mediators. 83 (4): 311–9. doi:10.1016/j.prostaglandins.2007.03.001. PMID 17499751.
  18. ↑ O'Flaherty JT, Cordes JF, Lee SL, Samuel M, Thomas MJ (December 1994). "Chemical and biological characterization of oxo-eicosatetraenoic acids". Biochimica et Biophysica Acta. 1201 (3): 505–15. doi:10.1016/0304-4165(94)90083-3. PMID 7803484.
  19. ↑ Enyedi B, Kala S, Nikolich-Zugich T, Niethammer P (September 2013). "Tissue damage detection by osmotic surveillance". Nature Cell Biology. 15 (9): 1123–30. doi:10.1038/ncb2818. PMC 3826879Freely accessible. PMID 23934216.
  20. 1 2 3 4 Cossette C, Gravel S, Reddy CN, Gore V, Chourey S, Ye Q, Snyder NW, Mesaros CA, Blair IA, Lavoie JP, Reinero CR, Rokach J, Powell WS (August 2015). "Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes". Biochemical Pharmacology. 96 (3): 247–55. doi:10.1016/j.bcp.2015.05.009. PMC 4830392Freely accessible. PMID 26032638.
  21. ↑ Grant GE, Rokach J, Powell WS (September 2009). "5-Oxo-ETE and the OXE receptor". Prostaglandins & Other Lipid Mediators. 89 (3–4): 98–104. doi:10.1016/j.prostaglandins.2009.05.002. PMC 2906239Freely accessible. PMID 19450703.
  22. ↑ Dworski R, Fitzgerald GA, Oates JA, Sheller JR (April 1994). "Effect of oral prednisone on airway inflammatory mediators in atopic asthma". American Journal of Respiratory and Critical Care Medicine. 149 (4 Pt 1): 953–9. doi:10.1164/ajrccm.149.4.8143061. PMID 8143061.
  23. ↑ O'Flaherty JT, Kuroki M, Nixon AB, Wijkander J, Yee E, Lee SL, Smitherman PK, Wykle RL, Daniel LW (July 1996). "5-Oxo-eicosatetraenoate is a broadly active, eosinophil-selective stimulus for human granulocytes". Journal of Immunology. 157 (1): 336–42. PMID 8683135.
  24. ↑ Chilton FH, O'Flaherty JT, Walsh CE, Thomas MJ, Wykle RL, DeChatelet LR, Waite BM (May 1982). "Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine". The Journal of Biological Chemistry. 257 (10): 5402–7. PMID 6802816.
  25. ↑ Swendsen CL, Ellis JM, Chilton FH, O'Flaherty JT, Wykle RL (May 1983). "1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187". Biochemical and Biophysical Research Communications. 113 (1): 72–9. doi:10.1016/0006-291x(83)90433-3. PMID 6407484.
  26. ↑ Wijkander J, O'Flaherty JT, Nixon AB, Wykle RL (November 1995). "5-Lipoxygenase products modulate the activity of the 85-kDa phospholipase A2 in human neutrophils". The Journal of Biological Chemistry. 270 (44): 26543–9. doi:10.1074/jbc.270.44.26543. PMID 7592874.
  27. ↑ Rubin P, Mollison KW (May 2007). "Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids". Prostaglandins & Other Lipid Mediators. 83 (3): 188–97. doi:10.1016/j.prostaglandins.2007.01.005. PMID 17481554.
  28. ↑ Copas JL, Borgeat P, Gardiner PJ (February 1982). "The actions of 5-, 12-, and 15-HETE on tracheobronchial smooth muscle". Prostaglandins, Leukotrienes, and Medicine. 8 (2): 105–14. doi:10.1016/s0262-1746(82)80002-4. PMID 6952280.
  29. ↑ Morin C, Rousseau E (January 2007). "Effects of 5-oxo-ETE and 14,15-EET on reactivity and Ca2+ sensitivity in guinea pig bronchi". Prostaglandins & Other Lipid Mediators. 82 (1–4): 30–41. doi:10.1016/j.prostaglandins.2006.05.012. PMID 17164130.
  30. ↑ Mercier F, Morin C, Cloutier M, Proteau S, Rokach J, Powell WS, Rousseau E (October 2004). "5-Oxo-ETE regulates tone of guinea pig airway smooth muscle via activation of Ca2+ pools and Rho-kinase pathway". American Journal of Physiology. Lung Cellular and Molecular Physiology. 287 (4): L631–40. doi:10.1152/ajplung.00005.2004. PMID 15090369.
  31. ↑ Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martínez A, Mulshine JL (February 1996). "Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling". The Journal of Clinical Investigation. 97 (3): 806–13. doi:10.1172/JCI118480. PMC 507119Freely accessible. PMID 8609238.
  32. ↑ Ding XZ, Tong WG, Adrian TE (2003). "Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer". Oncology. 65 (4): 285–94. doi:10.1159/000074640. PMID 14707447.
  33. ↑ Wang J, Yuen BH, Leung PC (February 1989). "Stimulation of progesterone and prostaglandin E2 production by lipoxygenase metabolites of arachidonic acid". FEBS Letters. 244 (1): 154–8. doi:10.1016/0014-5793(89)81182-2. PMID 2494061.
  34. ↑ Reddy GP, Prasad M, Sailesh S, Kumar YV, Reddanna P (June 1993). "Arachidonic acid metabolites as intratesticular factors controlling androgen production". International Journal of Andrology. 16 (3): 227–33. doi:10.1111/j.1365-2605.1993.tb01184.x. PMID 8359939.
  35. ↑ Wang XJ, Dyson MT, Jo Y, Eubank DW, Stocco DM (June 2003). "Involvement of 5-lipoxygenase metabolites of arachidonic acid in cyclic AMP-stimulated steroidogenesis and steroidogenic acute regulatory protein gene expression". The Journal of Steroid Biochemistry and Molecular Biology. 85 (2–5): 159–66. doi:10.1016/s0960-0760(03)00189-4. PMID 12943700.
  36. ↑ Wang X, Walsh LP, Reinhart AJ, Stocco DM (June 2000). "The role of arachidonic acid in steroidogenesis and steroidogenic acute regulatory (StAR) gene and protein expression". The Journal of Biological Chemistry. 275 (26): 20204–9. doi:10.1074/jbc.m003113200. PMID 10777507.
  37. ↑ Wang XJ, Dyson MT, Mondillo C, Patrignani Z, Pignataro O, Stocco DM (February 2002). "Interaction between arachidonic acid and cAMP signaling pathways enhances steroidogenesis and StAR gene expression in MA-10 Leydig tumor cells". Molecular and Cellular Endocrinology. 188 (1–2): 55–63. doi:10.1016/S0303-7207(01)00748-1. PMID 11911946.
  38. ↑ Gallwitz WE, Mundy GR, Lee CH, Qiao M, Roodman GD, Raftery M, Gaskell SJ, Bonewald LF (May 1993). "5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices". The Journal of Biological Chemistry. 268 (14): 10087–94. PMID 8486677.
  39. ↑ Traianedes K, Dallas MR, Garrett IR, Mundy GR, Bonewald LF (July 1998). "5-Lipoxygenase metabolites inhibit bone formation in vitro". Endocrinology. 139 (7): 3178–84. doi:10.1210/endo.139.7.6115. PMID 9645691.
  40. ↑ Pearson T, Zhang J, Arya P, Warren AY, Ortori C, Fakis A, Khan RN, Barrett DA (December 2010). "Measurement of vasoactive metabolites (hydroxyeicosatetraenoic and epoxyeicosatrienoic acids) in uterine tissues of normal and compromised human pregnancy". Journal of Hypertension. 28 (12): 2429–37. doi:10.1097/HJH.0b013e32833e86aa. PMID 20852449.
  41. ↑ Bennett PR, Elder MG, Myatt L (June 1987). "The effects of lipoxygenase metabolites of arachidonic acid on human myometrial contractility". Prostaglandins. 33 (6): 837–44. doi:10.1016/0090-6980(87)90112-2. PMID 2823315.
  42. ↑ Bennett PR, Chamberlain GV, Patel L, Elder MG, Myatt L (March 1990). "Mechanisms of parturition: the transfer of prostaglandin E2 and 5-hydroxyeicosatetraenoic acid across fetal membranes". American Journal of Obstetrics and Gynecology. 162 (3): 683–7. doi:10.1016/0002-9378(90)90984-F. PMID 2316568.
  43. ↑ Boulpaep, Walter F. Boron; Emile L. (2005). Medical physiology : a cellular and molecular approach (Updated ed.). Philadelphia, Pa.: Elsevier Saunders. ISBN 1416023283.
  44. ↑ Foley TD (June 1997). "5-HPETE is a potent inhibitor of neuronal Na+, K(+)-ATPase activity". Biochemical and Biophysical Research Communications. 235 (2): 374–6. doi:10.1006/bbrc.1997.6790. PMID 9199200.
  45. ↑ Richards CF, Johnson AR, Campbell WB (February 1986). "Specific incorporation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid into phosphatidylcholine in human endothelial cells". Biochimica et Biophysica Acta. 875 (3): 569–81. doi:10.1016/0005-2760(86)90079-2. PMID 3004591.

External links

This article is issued from Wikipedia - version of the 11/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.